The issuer is solely responsible for the content of this announcement.
China Resources Pharmaceutical Group Limited (Stock code: 03320.HK) stands as a premier, integrated pharmaceutical enterprise in China. Our comprehensive operations span the entire value chain, from R&D and manufacturing to distribution and retail. We host a robust portfolio of listed subsidiaries and maintain advanced innovation platforms dedicated to both chemical and biological pharmaceuticals. Our diverse products including chemical drugs, Traditional Chinese Medicine (TCM), biologics, health supplements, and medical devices, addressing a vast spectrum of therapeutic areas. We are the proud custodian of iconic brands such as "999", "Dong-E-E-Jiao", and "Jiangzhong". Guided by our mission to "Safeguard Human Health and Enhance Quality of Life," we are dedicated to evolving into a trusted, innovation-driven leader in pharmaceutical and healthcare sector.
Dong-E E-Jiao Co., Ltd. (000423.SZ) is an enterprise engaged in the production and operation of E-Jiao and related products. As a subsidiary of state-owned China Resources Group, it is primarily involved in the R&D, production, and sales of E-Jiao and related Chinese patent medicines, health foods, and food products. The company, formerly known as Shandong Dong-E E-Jiao Factory, was established in 1952, listed on the Shenzhen Stock Exchange in 1996, and joined China Resources Group in 2005. The company houses the National Gelatin Traditional Chinese Medicine Engineering Technology Research Center and a postdoctoral research workstation. It is recognized as a National High-Tech Enterprise, a National Innovative Enterprise, a National Intangible Cultural Heritage Heritage Enterprise, and a National Traditional Chinese Medicine Culture Publicity and Education Base. Its products are sold not only in the domestic market but also in over 10 countries and regions, including Southeast Asia, Europe, and the Americas.
AilsynBio is an AI-native biotechnology company dedicated to the rational design of differentiated therapeutics. By combining artificial intelligence, physics-based modeling, and deep medicinal chemistry expertise, the company delivers end-to-end drug discovery solutions spanning novel target identification, mechanism-of-action elucidation, and lead design and optimization. Validated through collaborations with multiple top-tier pharmaceutical companies, AilsynBio's technology offers industry-leading predictive accuracy and enables the delivery of IND-ready candidate molecules with greater efficiency, higher success rates, and a fraction of the time and cost required by conventional approaches.
RSS Feed 
